LAUSR

In contrast to the early acting bone morphogenetic protein 2, bone morphogenetic protein 7 (BMP7) plays a decisive role mainly in the late stages of bone formation. To overcome deactivation and degradation of expensive BMP7, we designed a novel long‐acting BMP7 release system based on poly(3‐hydroxybutyrate‐co‐4‐hydroxybutyrate) (P34HB) nanoparticles to enable the induction of osteogenic differentiation in human adipose mesenchymal stem cells (ADSCs). In order to improve the encapsulation efficiency of BMP7 and avoid damage by organic solvents, BMP7 was modified and protected using the biosurfactant soybean lecithin. In an in vitro test, BMP7‐soybean lecithin‐P34HB nanoparticles (BMP7‐SPNPs) showed a short initial burst of BMP7 release during the first 24h, followed by a steady increase to a cumulative 80% release in 20days. Compared with the rapid release of control P34HB nanoparticles without soybean phospholipids loaded with BMP7 without soybean lecithin, BMP7‐SPNPs significantly reduced the initial burst of BMP7 release and stabilized the content of BMP7 to allow long‐term osteogenic differentiation during the late phase of bone development. Human ADSCs treated with BMP7‐SPNPs showed higher alkaline phosphatase activity and higher expression levels of genetic markers of osteogenic differentiation compared with the control group. Thus, the results indicate that BMP7‐SPNPs can be used as a rapid and long‐acting BMP7 delivery system for osteogenic differentiation.